The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 12, 2012

Filed:

Nov. 24, 2008
Applicants:

Young Woo Park, Daejeon, KR;

So-young Choi, Daejoen, KR;

Ji Hyun Park, Gyeongsangnam-do, KR;

Jung Yu, Daejeon, KR;

Eun-jung Song, Daejeon, KR;

Sungsub Kim, Daejeon, KR;

Myeoung Hee Jang, Daejeon, KR;

Mi-ju Park, Daejeon, KR;

Je-ho Lee, Seoul, KR;

Jae Ryoung Hwang, Seoul, KR;

Inventors:

Young Woo Park, Daejeon, KR;

So-Young Choi, Daejoen, KR;

Ji Hyun Park, Gyeongsangnam-do, KR;

Jung Yu, Daejeon, KR;

Eun-Jung Song, Daejeon, KR;

Sungsub Kim, Daejeon, KR;

Myeoung Hee Jang, Daejeon, KR;

Mi-Ju Park, Daejeon, KR;

Je-Ho Lee, Seoul, KR;

Jae Ryoung Hwang, Seoul, KR;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); G01N 33/53 (2006.01); A61K 39/395 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention relates to a CD9-specific human antibody, more precisely a CD9-specific human antibody composed of human derived CD9-specific complementarity determining region (CDR) and framework region (FR). The human antibody of the present invention recognizes CD9 extracellular loop 2 domain (CD9-ECL2) as an epitope and thereby strongly binding thereto. The human antibody of the present invention also has CD9 antigen neutralizing effect and at the same time inhibiting effect on tumor cell lines. Therefore, it can be effectively used for the prevention and treatment of cancer overexpressing CD9.


Find Patent Forward Citations

Loading…